Bellevue Group AG Invests $180,000 in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Bellevue Group AG acquired a new stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 8,000 shares of the company’s stock, valued at approximately $180,000.

Several other hedge funds and other institutional investors have also modified their holdings of NRIX. Driehaus Capital Management LLC acquired a new position in Nurix Therapeutics during the 2nd quarter valued at $26,778,000. Candriam S.C.A. raised its position in shares of Nurix Therapeutics by 30.5% during the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock valued at $24,297,000 after buying an additional 272,136 shares during the last quarter. Affinity Asset Advisors LLC raised its position in shares of Nurix Therapeutics by 12.6% during the second quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company’s stock valued at $19,033,000 after buying an additional 101,747 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Nurix Therapeutics by 60.2% in the second quarter. Millennium Management LLC now owns 599,623 shares of the company’s stock valued at $12,514,000 after buying an additional 225,374 shares during the period. Finally, FMR LLC grew its position in Nurix Therapeutics by 675.9% during the third quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after buying an additional 511,256 shares in the last quarter.

Nurix Therapeutics Trading Up 4.1 %

NASDAQ NRIX opened at $22.11 on Monday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -7.60 and a beta of 2.20. Nurix Therapeutics, Inc. has a 1-year low of $5.95 and a 1-year high of $29.56. The company has a 50 day moving average of $24.02 and a 200-day moving average of $21.84.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.67). The company had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. On average, analysts forecast that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on NRIX shares. Royal Bank of Canada cut their price target on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 14th. HC Wainwright upped their target price on Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Stephens reiterated an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a research note on Monday, October 14th. Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 price target on the stock. Finally, UBS Group began coverage on shares of Nurix Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective for the company. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total value of $86,096.88. Following the transaction, the chief financial officer now directly owns 33,724 shares in the company, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Ring sold 5,760 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total value of $128,044.80. Following the sale, the insider now owns 24,592 shares of the company’s stock, valued at approximately $546,680.16. The trade was a 18.98 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,451 shares of company stock valued at $663,160. Insiders own 7.20% of the company’s stock.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.